Clinical Trial – Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome

The investigators have previously studied the efficacy of hyperbaric oxygen therapy (HBOT) as
a treatment for Fibromyalgia syndrome (FMS) in a prospective, active control, crossover
clinical trial. The results demonstrated significant amelioration of all FMS symptoms, with
significant improvement in life quality; furthermore, the investigators were able to
demonstrate significant neuroplasticity on SPECT imaging, with a decrease of the
hyperactivity in posterior regions and elevation of the reduced activity in frontal areas.

In the proposed study, the investigators intend to both repeat and expand our previous
findings, treating FMS patients with HBOT while performing an extensive of evaluation both
before and after treatment.

In the current study, the investigators plan to compare HBOT to current standard of care of
FMS (pharmacological and non – pharmacological).

Clinical Trial – Heavy Bupivacaine in Peribulbar Block

Most of the ophthalmic procedures are performed under local anesthesia as the patient is
often elderly and with diseases. This may increase the risk of morbidity and mortality under
general anesthesia. Different eye blocks have been practiced with great success. Moreover, it
is associated with less hemodynamic instability, less respiratory depression, better
postoperative pain relief, and less nausea and vomiting than general anesthesia. It is also
associated with a reduction in stress response, maintained oxygen saturation and
cardiovascular stability, in addition to the production of good akinesia and anesthesia
alleviating occulo-medullary reflexes, all make local anesthesia more superior and safe
technique.

Hyperbaric oxygen for persistent post-concussive symptoms: long-term follow-up.

We report results of an observational cohort study investigating long-term follow-up in participants from two completed United States military trials of hyperbaric oxygen (HBO₂) for persistent post-concussive symptoms (PCS), as well as challenges in recruitment and retention in active-duty military personnel. After informed consent, participants completed an electronic survey assessing PCS, post-traumatic stress disorder (PTSD), anxiety, depression and quality of life. Of 132 HBO₂ study participants, 40 (30%) completed the survey (42 could not be contacted; 50 were lost to follow-up or declined). All were male, age 28.1 ±6.6 years (mean ±1SD). Time to follow-up was 39.2 ±6.1 months.